The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotechnology Index has returned 18.35% so far this year, which beats the 3.74% return churned out by hedge funds across all strategies.
The shakedown of healthcare stocks provided hedge funds with a favorable entry point. Pharma and biotech companies have been the favorite buys of hedge funds over the past few quarters.
Baupost expands healthcare portfolio
Baupost Group is among the funds who have increased their healthcare holdings with...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
